Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol...
Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous...
View ArticleThe Lancet publishes phase 3 clinical study data on VIVITROL for treatment of...
Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet....
View ArticleElan Drug Technologies, Alkermes merge to form new company in Ireland
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug...
View ArticleAlkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression
Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and...
View ArticlePositive topline results from Alkermes ALKS 9070 phase 1b study for...
Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.
View ArticlePositive results from Alkermes VIVITROL addiction study
Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress...
View ArticleAlkermes reports 38% of year-over-year revenue growth from key products
Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on...
View ArticleGeneric drug gabapentin appears to be safe, effective in treating alcohol...
The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a...
View ArticleAlkermes reports financial results for first quarter of 2014
Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and...
View ArticleMass. to spend $20 million to combat opioid use
Governor Deval Patrick announced the plan Tuesday that will also team with five other New England states to upgrade treatment and expand coverage abuse of the drugs.
View ArticleBMC opens new opioid urgent care center to treat patients with substance use...
Boston Medical Center, in collaboration with the Massachusetts Department of Public Health and the Boston Public Health Commission, has launched a new opioid urgent care center to give patients with...
View ArticlePeople in recovery worry GOP Medicaid cuts would put treatment out of reach
Republicans in both the House and the Senate are considering big cuts to Medicaid. But those cuts endanger addiction treatment, which many people receive through the government health insurance program.
View ArticleElan Drug Technologies, Alkermes merge to form new company in Ireland
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug...
View ArticleAlkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression
Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and...
View ArticlePositive topline results from Alkermes ALKS 9070 phase 1b study for...
Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.
View ArticlePositive results from Alkermes VIVITROL addiction study
Alkermes plc today presented positive results from a long-term study of VIVITROL (naltrexone for extended-release injectable suspension) at the 24th Annual U.S. Psychiatric and Mental Health Congress...
View ArticleAlkermes reports 38% of year-over-year revenue growth from key products
Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on...
View ArticleGeneric drug gabapentin appears to be safe, effective in treating alcohol...
The generic drug gabapentin, which is already widely prescribed for epilepsy and some kinds of pain, appears to be safe and effective in the treatment of alcohol dependence. The finding comes from a...
View ArticleAlkermes reports financial results for first quarter of 2014
Alkermes plc today reported financial results for the first quarter of 2014. "During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and...
View ArticleMass. to spend $20 million to combat opioid use
Governor Deval Patrick announced the plan Tuesday that will also team with five other New England states to upgrade treatment and expand coverage abuse of the drugs.
View Article
More Pages to Explore .....